UK-based private equity and venture capital firm Kingsley Capital has invested in a new Oxford University spin-out that will research the use of non-addictive medicinal cannabis to treat chronic conditions.

Kingsley has provided £10 million of funding to Oxford Cannabinoid Technologies, which will seek to identify new medicinal therapies by researching to role of cannabinoids in treatments.